Compare Hims and Hers Health Inc (HIMS) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs ProShares UltraPro S&P500 — how do they compare? Hims and Hers Health Inc trades at $28.37 (market cap $6.55B), while ProShares UltraPro S&P500 trades at $154.55 (market cap $5.55B). The key difference: Hims and Hers Health Inc is the larger of the two by market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and ProShares UltraPro S&P500 for 29 Days on average.
| HIMS | UPRO | |
|---|---|---|
Market Cap | $6.55B | $5.55B |
Volume | 14,842,814 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $62.76 | $157.66 |
52-Week Low | $14.52 | $89.29 |
Typical Hold Time | 21 Days | 29 Days |
Enterprise Value | $7.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.
The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.
UPRO trades at $155.21, down 0.77% on the day, while maintaining a bullish technical stance with strong moving average support. The stock shows neutral momentum oscillators but benefits from positive market sentiment around S&P 500 exposure. Recent news highlights strong corporate earnings growth expectations of 35% for 2026, though concerns exist about concentration risks in top holdings and potential profit growth slowdown to 15% in 2027.
The outlook remains cautiously optimistic given the S&P 500's historical bullish seasonal patterns and AI-driven earnings growth, though investors face risks from market concentration, elevated valuations, and potential Federal Reserve policy impacts. Wall Street expects continued gains but acknowledges the need for selective positioning amid changing market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
